Exchange
Euronext Paris
Every company in the roster listed on Euronext Paris.
Research
Compare financial metrics on this exchange
Research adds market cap, cash, runway and annualized R&D metrics with metric-specific sorting.
Views
6 of 6 companies
| Company | Pipeline | Most advanced | Next readout |
|---|---|---|---|
 GenfitGNFT · Euronext Paris | 3 assets: 1 approved, 1 Ph 2, 1 other | GNS561Phase 1/2 · Cholangiocarcinoma with KRAS Mutation | Dec 2027GNS561 · Phase 1/2 |
 Innate PharmaIPH · Euronext Paris | 3 assets: 1 Ph 3, 1 Ph 1, 1 other | MonalizumabPhase 3 · Non-Small Cell Lung CancerPartial signal | Apr 2028IPH4502 · Phase 1 |
 AB ScienceAB · Euronext Paris | 2 assets: 1 Ph 3, 1 Ph 2 | MasitinibPhase 3 · Alzheimer's DiseaseReliable signal | Dec 2027Masitinib · Phase 3 |
 OSE ImmunotherapeuticsOSE · Euronext Paris | 2 assets: 1 Ph 3, 1 Ph 2 | OSE2101Phase 3 · Non-Small Cell Lung CancerPartial signal | 15 Dec 2027OSE2101 · Phase 3 |
 IpsenIPN · Euronext Paris | 1 asset: 1 Ph 2 | Mesdopetam (IRL790)Phase 2 · Parkinson's DiseasePartial signal | None on record |
 TransgeneTNG · Euronext Paris | 1 asset: 1 Ph 2 | T101Phase 2 · Chronic Hepatitis B | None on record |
Next readout: the earliest estimated primary completion of a trial the company or a partner on the asset runs (ClinicalTrials.gov).